Twitter | Search | |
Search Refresh
Sonia Glez Costas Mar 16
/Nivolumab Combo Shows Promise in Richter’s Transformation | This combination appears to be safe and responses seem to be most promising in Richter’s transformation, where there is a huge unmet need for effective treatments Cancer Network
Reply Retweet Like
Michele Nadeem-Baker Aug 7
Checkout study on: , a next generation BTK bioavailable btk inhibitor specifically designed to improve on the safety & efficacy of first-generation btk inhibitors such as for the treatment of
Reply Retweet Like
The Lancet Oncology Aug 9
Reply Retweet Like
Helen Ong Jan 18
Provides Update on Phase 3 Study of Ibrutinib in Metastatic Pancreatic Cancer So, failed in metastatic panic cancer. Perhaps $APTO’s GC’806 has a better shot, being a BTK &multi kinase (FLT3) inhibitor w/ less propensity for resistance
Reply Retweet Like
AJMC Dec 3
alone better than chemoimmunotherapy as frontline in older patients with CLL
Reply Retweet Like
Joe Aug 6
The 1st CG-806 CLL patient that previously failed , venetoclax, rituximab and idelalisib, and that patient now has successfully received more than 50 doses of CG-806. The 2nd patient to be enrolled is planned to receive oral doses of 300mg twice daily.
Reply Retweet Like
CLL Ireland Feb 8
The nonchemothetapy combo of plus obinutuzumab for the frontline treatment of patients with is discussed "the results of the study were outstanding, with impressive progression-free survival and a nearly 100% response rate" | via
Reply Retweet Like
Franck Thuny May 14
Ibrutinib-related AF: pre-therapeutic left atrial volume index >40mL/m2 may help to identify high-risk patients as suggested by Dr Florian Baptiste paper from our French group.
Reply Retweet Like
Debra Robertson Apr 1
Tried explaining the patient acces schemes to a couple of colleagues today when the new tablet strengths were announced. Felt like I should change my name to 'Chuckle'!
Reply Retweet Like
Hayder Saeed, MD Mar 23
⁩ et al, + RCHOP improved EFS PFS and OS in <60 yo with DLBCL
Reply Retweet Like
Jeff Sharman Jul 14
Most careers are built by getting reliable singles. Doubles are great and triples are rare. Everyone knows when a home run is hit. We just want our fellows to crowd the plate and get hit by a pitch. Glad I ignored and helped write the first in human study
Reply Retweet Like
Silvana Novelli Dec 9
After reading DUO trial results in R/R CLL/SLL and SAE: Duvelisib may be ok for patients with heart disease in need of anticoagulation or with lots of medications and interactions or with renal disease that makes difficult to use or
Reply Retweet Like
CLL Ireland Jan 11
Prof. John Gribben provides an overview of key updates in treatment for including the ECOG, MURANO and iLLUMINATE studies from investigating vs. FCR standard filmed at | via
Reply Retweet Like
Tom Henry, MBA, RPh, CPh May 9
Things to Know About Ibrutinib – CLL Society
Reply Retweet Like
Bachar Samra, MD Jun 4
is now published! Immediately practice-changing trial for frontline unfit patients. Time limited, highly effective, 88% PFS at 2y, high MRD negativity and well tolerated. How does this compare to + ?
Reply Retweet Like
Silvana Novelli Jul 19
The updated results have been published. No doubts that the combination of is convenient. But a large proportion of patients have received ibru and some have acquired mutations. Wait for results.
Reply Retweet Like
Miguel Canales Dec 14
Ibrutinib for the treatment of Bing-Neel syndrome: showed rapid and durable symptomatic and radiological responses in patients with BNS
Reply Retweet Like
Firas El Chaer, MD 💉💊🔬 Apr 2
is being used as a single therapy or w/ steroids for tx of w/ potential ⬆ IFD could be an option if concerns for QT prolongation & DDI & no need for levels monitoring
Reply Retweet Like
UpToDate Jan 4
: Trial finds improved progression-free and overall survival with + , vs. fludarabine + cyclophosphamide + rituximab, for fit patients <70 years with unmutated chronic lymphocytic (CLL)
Reply Retweet Like
Toby Eyre Aug 1
Shanafelt et al Lower % of –rituximab (8.3%) vs chemoimmunotherapy (59.2%) were MRD-negative at cycle 12 yet PFS + OS advantage overall in favour of I-R. MRD isn’t everything in and is treatment specific
Reply Retweet Like